Health Care [ 9/12 ] | Pharmaceuticals [ 57/73 ]
NYSE | Common Stock
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products.
This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements.
The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations.
The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management.
Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | 19.11 Decreased by -75.61% | 17.13 Increased by +11.56% |
| Jan 28, 25 | 16.94 Decreased by -79.55% | 16.15 Increased by +4.86% |
| Oct 25, 24 | 0.18 Decreased by -99.80% | 0.98 Decreased by -81.63% |
| Jul 27, 24 | 83.46 Increased by +8.00 K% | 78.22 Increased by +6.70% |
| May 7, 24 | 78.35 Increased by +11.09 K% | 68.45 Increased by +14.46% |
| Jan 30, 24 | 82.81 Increased by +9.00 K% | 70.43 Increased by +17.58% |
| Nov 2, 23 | 88.91 Increased by +10.74 K% | 69.65 Increased by +27.65% |
| Jul 26, 23 | 1.03 Increased by +14.44% | 0.77 Increased by +33.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 85.06 B Increased by +20.09% | 15.94 B Increased by +21.94% | Increased by +18.74% Increased by +1.54% |
| Dec 31, 24 | 83.59 B Increased by +15.85% | 14.13 B Increased by +2.49% | Increased by +16.91% Decreased by -11.53% |
| Sep 30, 24 | 80.16 B Increased by +16.51% | 12.55 B Decreased by -15.18% | Increased by +15.66% Decreased by -27.20% |
| Jun 30, 24 | 76.73 B Increased by +13.87% | 13.92 B Decreased by -0.75% | Increased by +18.14% Decreased by -12.83% |
| Mar 31, 24 | 70.83 B Increased by +12.48% | 13.07 B Increased by +36.26% | Increased by +18.45% Increased by +21.14% |
| Dec 31, 23 | 72.15 B Increased by +6.57% | 13.79 B Increased by +10.57% | Increased by +19.11% Increased by +3.75% |
| Sep 30, 23 | 68.80 B Increased by +9.11% | 14.80 B Increased by +33.00% | Increased by +21.51% Increased by +21.89% |
| Jun 30, 23 | 67.38 B Increased by +29.20% | 14.03 B Increased by +18.10% | Increased by +20.81% Decreased by -8.60% |